Inversago Pharma
metabolic and
fibrotic diseases
About Inversago Pharma
OUR MISSION
Inversago is a clinical stage biopharmaceutical company
dedicated to developing therapies for patients suffering from metabolic and fibrotic diseases.
ABOUT INVERSAGO PHARMA
Based in Montreal Canada, Inversago Pharma is the leader in the development of peripherally acting CB1 receptor (CB1r) blocker therapies designed to help patients with complications associated with metabolic and fibrotic diseases. The company’s lead program INV-202, targeting metabolic disorders, is being evaluated in two Phase 2 studies: for patients with diabetic kidney disease on one hand, and patients with obesity on the other hand.
The Peripheral CB1 Company
Disease Focus
We are advancing our pipeline of innovative peripherally-acting CB1r blockers to improve the lives of patients with metabolic and fibrotic diseases.
Inversago is focusing on complications of diabetes (type 1 and type 2) and obesity, including diabetic kidney disease, non-alcoholic steatohepatitis, and hyperlipidemia.
In addition, CB1r blockade offers an important alternative therapy for fibrotic diseases and we are developing compounds to treat diseases like pulmonary fibrosis, fibrotic liver and kidney diseases, and systemic sclerosis.
Our Approach
To address the pathophysiology of metabolic disorders, Inversago focuses its research and development on regulating the peripheral CB1 receptors, which are involved in many of these conditions.
A safe and potent CB1 inhibitor would have the potential to block the biological processes induced by supraphysiological CB1 activation and provide a novel treatment to patients.
Pipeline
We are building our innovative pipeline with the singular focus to advance peripherally acting CB1r blockers to improve the lives of patients.
The company’s development programs aim to provide novel therapies for the treatment of a series of metabolic conditions, such as diabetic kidney disease, type 1 and type 2 diabetes, obesity, non-alcoholic steatohepatitis, hyperlipidemia, and fibrotic indications such as progressive fibrosis – interstitial lung disease.
